Otherwise, it would lead to diseases like acute (sudden) hepatitis (inflammation), chronic (long duration) hepatitis, fatty ...

The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

Identify the warning signs of hepatitis before they become serious. From subtle fatigue to more obvious symptoms, recognizing liver inflammation early can save.

The liver is the body’s chemical factory, where most metabolic processes take place. It processes everything you eat and drink, converting them into energy and essential nutrients. Additionally, the ...

While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

Rezdiffra (resmetirom) is a prescription drug used to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) in adults in certain ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH ... with 34% resolving symptoms at low dose, 44% at high ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...